We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Pneumococcal vaccine

News List

DoctorOnCall, Pfizer and UOB Malaysia form Malaysia's first tripartite collaboration to improve children's access to pneumococcal vaccine prnasia
June 16, 2021
DoctorOnCall, Pfizer and UOB Malaysia today jointly launched "ASK4VACCINE", a financing programme that aims to improve children's access to pneumococcal vaccine in Malaysia.
FDA accepts priority review of Merck’s pneumococcal vaccine pharmaceutical-technology
January 14, 2021
The US Food and Drug Administration (FDA) has accepted priority review of the Biologics License Application (BLA) of Merck’s investigational 15-valent pneumococcal conjugate vaccine candidate, V114, for preventing invasive pneumococcal disease in adults.
Astellas and Affinivax’s novel pneumococcal vaccine enters human testing fiercepharma
February 24, 2019
About two years ago, Astellas licensed a novel pneumococcal vaccine technology from Affinivax with eyes on Pfizer’s Prevnar 13. Now, the pair has officially entered human testing.
Astellas, Affinivax team up on 'next-gen' pneumococcal vaccine to target Pfizer’s Prevnar fiercepharma
March 01, 2017
Astellas just forged a licensing deal with Affinivax to develop a pneumococcal vaccine. Their target? Pfizer’s Prevnar 13—the world’s bestselling vaccine.